RANDY’S Trial: Could Existing Medications Help Expand Surgical Options for Appendix Cancer?

Could existing medications help expand surgical options for patients with appendix cancer? A newly launched clinical trial at the Allegheny Health Network (AHN) Cancer Center in Pittsburgh is exploring an innovative approach to a challenge faced by some patients with appendix cancer and other peritoneal malignancies: dense scar tissue (fibrosis) that can make surgery more difficult or, in some cases, prevent it from being an option.

About the RANDY’S Trial

The RANDY’S Trial (Repurposed And Naturally-Derived Drugs for the Treatment of Fibrosis in Peritoneal Carcinomatosis) is led by Dr. Patrick Wagner, a member of ACPMP’s Scientific Advisory Board. The study will investigate whether medications already approved by the FDA for other conditions could be repurposed to modify this scar tissue and potentially make cytoreductive surgery (CRS) safer or more feasible for certain patients.

Could addressing fibrosis help expand surgical possibilities for patients who might otherwise be considered ineligible? That’s the question researchers hope to answer.

Trial status

The trial is not yet open to enrollment. ACPMP looks forward to sharing more about this research and the science behind it in an upcoming episode of The Appy Files, our podcast, when the trial is closer to opening. We will also add it to ACPMP’s Clinical Trials Database once it is listed.

Learn more

Read AHN’s announcement and the Abdominal Cancers Alliance’s overview.

This summary is for general information only and is not medical advice. Please talk with your care team about what this research may mean for you.